Heba Youssef: Anticoagulation Bridging – A Clinical Summary Every Practitioner Should Know
Heba Youssef, Clinical Nutrition Pharmacist at Helwan General Hospital, shared a post on LinkedIn:
“Anticoagulation Bridging:
A Clinical Summary Every Practitioner Should Know
Navigating perioperative anticoagulation decisions can be complex — but getting it right is critical for patient safety.
Here are the key clinical pearls from the latest evidence and CHEST 2022 Guidelines:
Why Bridging Therapy Exists?
When initiating warfarin, Protein C drops rapidly while Prothrombin (Factor II) persists for 42–72 hours — creating a transient ‘hypercoagulable‘ window.
Overlapping with UFH or LMWH for a minimum of 5 days bridges this gap safely.
The 5-Day Rule
Stop heparin/LMWH ‘only’ when BOTH conditions are met:
- INR ≥ 2.0
- INR therapeutic for ≥ 24 hours (or two consecutive therapeutic readings)
Routine Perioperative Bridging? Not Recommended.
CHEST 2022 states routine heparin bridging is generally Not recommended for most patients — increased bleeding risk with little to no reduction in thromboembolism.
Reserve it for selected high-risk cases: mechanical heart valves, recent VTE < 3 months, or recent arterial thromboembolism.
DOACs: No Bridging Needed.
Their short half-life and rapid onset make perioperative bridging unnecessary.
Always Watch for HIT.
Platelet drop > 50%, typically 5–10 days post-exposure? Suspect Heparin-Induced Thrombocytopenia.
Stop all heparin immediately and switch to a non-heparin anticoagulant (Argatroban, Fondaparinux, or Bivalirudin).
Reversal When It Matters.
- UFH reversal with Protamine Sulfate
- Life-threatening warfarin bleeding reversal with 4-Factor PCC and IV Vitamin K (faster and more sustained than FFP)
Sound anticoagulation management is where pharmacology, clinical judgment, and patient safety converge.
These principles save lives when applied correctly.
What aspect of anticoagulation bridging do you find most challenging in clinical practice? ”
Stay updated with Hemostasis Today.
-
Jun 4, 2026, 15:10Dipanjana Datta: Genetic Spectrum of Hemophilia and Carrier Screening in Families of Persons with Hemophilia
-
Jun 4, 2026, 15:07Zain Khalpey: Key Differences Between NSTEMI and STEMI
-
Jun 4, 2026, 15:06Faisal Alghamdi: Iron Overload in Thalassemia Is Preventable – But Prevention Takes More Than Prescribing Drugs
-
Jun 4, 2026, 14:52Seema Dawood: Hemoglobin Typing Interpretation
-
Jun 4, 2026, 13:58Dietmar Dammerer: How Should We Manage Traumatic Brain Injury When on Anticoagulants?
-
Jun 4, 2026, 13:54Yaariv Khaykin: AI ECG Analysis Uncovers Hidden AF Associated With Future Stroke Risk
-
Jun 4, 2026, 13:50Gene Nudelman: Can a Hemostatic Gauze Perform When Blood Clotting is Impaired?
-
Jun 4, 2026, 13:45Edward Lee Carter: The First-Ever AHA/ACC Acute PE Guideline Is Here
-
Jun 4, 2026, 13:38Denis Oduor: The Role of Expectant Fathers in Saving Mothers and Newborns